Acquired Idiopathic Generalized Anhidrosis as a Late‐Onset Immune‐Related Adverse Event of Pembrolizumab in a Patient With Lung Adenocarcinoma: A Case Report and Review of the Literature
The Journal of Dermatology · 2026-07 · 53 (7) · 1072-1076
DOI: 10.1111/1346-8138.70306 ↗Kurz gefasst
Fallbericht in der Zeitschrift The Journal of Dermatology, online erschienen am 11.05.2026. Verfasst von Ayano Maruyama und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Adenocarcinoma of Lung, Lung Neoplasms, Hypohidrosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Acquired idiopathic generalized anhidrosis (AIGA) is a rare disorder of sweating that can be life‐threatening owing to the risk of heat stroke. AIGA as an immune‐related adverse event (irAE) of immune checkpoint inhibitors (ICIs) has been reported in only three cases. We report a 69‐year‐old man with unresectable lung adenocarcinoma (cT1N2M1b, Stage 4A) with hepatic metastasis who developed generalized anhidrosis after approximately 2 years (30 cycles) of pembrolizumab monotherapy. EGFR, ALK, and ROS1 were negative, and programmed death‐ligand 1 (PD‐L1) tumor proportion score (TPS; 22C3 antibody) was 90%–100%. Sweat testing revealed anhidrosis exceeding 75% of the body surface. Acetylcholine injection testing indicated idiopathic pure sudomotor failure (IPSF)‐type dysfunction. Skin biopsy revealed site‐dependent findings: peri‐eccrine lymphocytic infiltration involving the sweat glands and ducts in the sweating area (axilla) and prominent peri‐eccrine fibrosis in the anhidrotic area (left forearm). Serum carcinoembryonic antigen (CEA) was elevated to 16.7 ng/mL without tumor progression, prompting diagnostic workup including colonoscopy, which revealed no abnormalities. The patient was treated with three courses of methylprednisolone pulse therapy (1000 mg/day × 3 days) over 7 months and fexofenadine, resulting in partial sweating recovery and CEA decline to 3.0 ng/mL. Pembrolizumab was continued throughout without interruption, and the patient maintained durable stable disease (SD) over approximately 45 months (alive at last follow‐up). This case demonstrates the histopathological spectrum of ICI‐induced AIGA from inflammation to fibrosis within a single patient, and highlights CEA elevation as both a diagnostic clue and a potential pitfall in oncological practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
ORCID-Profile: Ayano Maruyama, Takeshi Fukumoto
Zitieren
APA
Maruyama, A., Sotozono, A., & Fukumoto, T. (2026). Acquired Idiopathic Generalized Anhidrosis as a Late‐Onset Immune‐Related Adverse Event of Pembrolizumab in a Patient With Lung Adenocarcinoma: A Case Report and Review of the Literature. The Journal of Dermatology, 53(7), 1072-1076. https://doi.org/10.1111/1346-8138.70306
Vancouver
Maruyama A, Sotozono A, Fukumoto T. Acquired Idiopathic Generalized Anhidrosis as a Late‐Onset Immune‐Related Adverse Event of Pembrolizumab in a Patient With Lung Adenocarcinoma: A Case Report and Review of the Literature. The Journal of Dermatology. 2026;53(7):1072-1076. doi:10.1111/1346-8138.70306
BibTeX
@article{Maruyama2026,
author = {Maruyama, Ayano and Sotozono, Ayaka and Fukumoto, Takeshi},
title = {Acquired Idiopathic Generalized Anhidrosis as a Late‐Onset Immune‐Related Adverse Event of Pembrolizumab in a Patient With Lung Adenocarcinoma: A Case Report and Review of the Literature},
journal = {The Journal of Dermatology},
year = {2026},
volume = {53},
number = {7},
pages = {1072--1076},
doi = {10.1111/1346-8138.70306}
}
EUVIMED